Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B

The U.S. Food and Drug Administration approved GSK’s drug bepirovirsen, sold as Hibsago, for chronic hepatitis B treatment. In two phase‑3 trials, 233 of 1,220 patients (19%) achieved a functional cure after a six‑month course, while none of 614 placebo participants did. The approval applies to U.S. patients.

Source: Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B — ScienceAlert

Watch: the original footage ↗

A daily AI-made news meme from Jester · Nov 5, 2026.